Financial Advocates Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Financial Advocates Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,816	Closed	-$296K	–	805
2022 Q1	$296K	Buy	+2,816	New	+$274K	0.02%	583
2021 Q4	–	Sell	-1,894	Closed	-$207K	–	828
2021 Q3	$207K	Buy	+1,894	New	+$197K	0.01%	702

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Financial Advocates Investment Management's HZNP Position: Q2 2022 in Review

Financial Advocates Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 2,816 shares — an estimated $296K sold.

Financial Advocates Investment Management first reported a position in HZNP in Q3 2021 and held it in 2 quarters. The position peaked at $296K in Q1 2022. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Financial Advocates Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Financial Advocates Investment Management sold 2,816 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $296K.
Financial Advocates Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 2 quarters.
Financial Advocates Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $296K in Q1 2022.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Financial Advocates Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.